Surprising
A peanut allergy trial found that a tiny 30 mg daily dose raised tolerance thresholds as effectively as a standard 300 mg dose — with fewer dropouts and side effects.
This small, year-long clinical trial in allergic children suggests that a much lower maintenance dose might work just as well as the typical higher one, but because this is among the first studies to test that comparison, the finding needs replication before it changes practice.
Kids with peanut allergy were given either a very low (30 mg) or standard (300 mg) daily maintenance dose of peanut protein. The lower dose increased how much peanut they could safely tolerate about as much as the higher dose, but fewer children quit the study or had severe reactions. The caveat: this was a small, single trial in a clinical setting, so the results may not apply to everyone with peanut allergy.
Where this fits in the evidence
This is among the first studies we've indexed on Peanut Protein for Increased Tolerance to Peanut Protein — treat it as an early signal until more research accumulates.
The study
Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses.
- Randomized Controlled Trial (RCT)
- n = 51
- 2026-01
- The journal of allergy and clinical immunology. In practice
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.